David Nemazee
Overview
Explore the profile of David Nemazee including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
119
Citations
6953
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Dacon C, Peng L, Lin T, Tucker C, Lee C, Cong Y, et al.
Cell Host Microbe
. 2022 Nov;
31(1):97-111.e12.
PMID: 36347257
Humanity has faced three recent outbreaks of novel betacoronaviruses, emphasizing the need to develop approaches that broadly target coronaviruses. Here, we identify 55 monoclonal antibodies from COVID-19 convalescent donors that...
12.
Zhao F, Keating C, Ozorowski G, Shaabani N, Francino-Urdaniz I, Barman S, et al.
iScience
. 2022 Aug;
25(9):104914.
PMID: 35971553
The rapid spread of SARS-CoV-2 variants poses a constant threat of escape from monoclonal antibody and vaccine countermeasures. Mutations in the ACE2 receptor binding site on the surface S protein...
13.
He W, Yuan M, Callaghan S, Musharrafieh R, Song G, Silva M, et al.
Sci Transl Med
. 2022 Aug;
14(657):eabl9605.
PMID: 35947674
To prepare for future coronavirus (CoV) pandemics, it is desirable to generate vaccines capable of eliciting broadly neutralizing antibody responses to CoVs. Here, we show that immunization of macaques with...
14.
Okoreeh M, Kennedy D, Olumide Emmanuel A, Veselits M, Moshin A, Ladd R, et al.
Sci Immunol
. 2022 Aug;
7(74):eabm1664.
PMID: 35930652
During B lymphopoiesis, B cell progenitors progress through alternating and mutually exclusive stages of clonal expansion and immunoglobulin (Ig) gene rearrangements. Great diversity is generated through the stochastic recombination of...
15.
Dacon C, Tucker C, Peng L, Lee C, Lin T, Yuan M, et al.
Science
. 2022 Jul;
377(6607):728-735.
PMID: 35857439
The potential for future coronavirus outbreaks highlights the need to broadly target this group of pathogens. We used an epitope-agnostic approach to identify six monoclonal antibodies that bind to spike...
16.
Yuan M, Zhu X, He W, Zhou P, Kaku C, Capozzola T, et al.
Proc Natl Acad Sci U S A
. 2022 Jun;
119(29):e2205784119.
PMID: 35767670
Many neutralizing antibodies (nAbs) elicited to ancestral severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) through natural infection and vaccination have reduced effectiveness to SARS-CoV-2 variants. Here, we show that therapeutic...
17.
Nahmad A, Lazzarotto C, Zelikson N, Kustin T, Tenuta M, Huang D, et al.
Nat Biotechnol
. 2022 Jun;
40(8):1241-1249.
PMID: 35681059
Transplantation of B cells engineered ex vivo to secrete broadly neutralizing antibodies (bNAbs) has shown efficacy in disease models. However, clinical translation of this approach would require specialized medical centers,...
18.
Dacon C, Tucker C, Peng L, Lee C, Lin T, Yuan M, et al.
bioRxiv
. 2022 Apr;
PMID: 35441178
One-sentence Summary: Rare monoclonal antibodies from COVID-19 convalescent individuals broadly neutralize coronaviruses by targeting the fusion peptide.
19.
Ferrara F, Erasmus M, DAngelo S, Leal-Lopes C, Teixeira A, Choudhary A, et al.
Nat Commun
. 2022 Apr;
13(1):2097.
PMID: 35414071
No abstract available.
20.
Yuan M, Zhu X, He W, Zhou P, Kaku C, Capozzola T, et al.
bioRxiv
. 2022 Mar;
PMID: 35313576
Many neutralizing antibodies (nAbs) elicited to ancestral SARS-CoV-2 through natural infection and vaccination generally have reduced effectiveness to SARS-CoV-2 variants. Here we show therapeutic antibody ADG20 is able to neutralize...